Boehringer Ingelheim

News

Novo Nordisk, Lilly highlight oral obesity drugs at ADA

New data from Novo Nordisk’s phase 3 trial of an oral, high-dose formulation of semaglutide reinforces its potential as a weight-loss therapy in obesity, but Eli Lilly is

News

Jardiance is first SGLT2 given FDA OK for use in children

With rates of juvenile type 2 diabetes rocketing in the US, doctors now have access to an alternative oral therapy – the first new oral option for more than 20 years.

News

Boehringer loses bid to be shielded from Zantac litigation

Sanofi says it has won an arbitration dispute with Boehringer Ingelheim, in which the latter had tried to protect itself from liabilities that may arise from ongoing litig

News

Boehringer shows its hand in obesity

Boehringer Ingelheim and partner Zealand Pharma have reported new clinical data in obesity for their dual glucagon/GLP1 agonist BI 456906, setting up a possible challenge

News

Farxiga back on level pegging in heart failure

The FDA has approved AstraZeneca’s SGLT2 inhibitor Farxiga as a treatment candidate for all patients with heart failure, putting the drug back in contention with rival Jar

News

NICE blocks wider use of Jardiance, Forxiga in heart failure

Eli Lilly and Boehringer Ingelheim's Jardiance and AstraZeneca's Forxiga have not been recommended for NHS use as a treatment for symptomatic chronic heart failure (CHF) w

Novo Nordisk, Lilly highlight oral obesity drugs at ADA

Jardiance is first SGLT2 given FDA OK for use in children

Boehringer loses bid to be shielded from Zantac litigation

Boehringer shows its hand in obesity

Farxiga back on level pegging in heart failure

NICE blocks wider use of Jardiance, Forxiga in heart failure

AI for the planet, AI for life sciences – with Patrick Leung

How to meet your physicians where they are online

Boehringer Ingelheim

Editor's Picks